Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A22 (S-(3,4-dichlorobenzyl)isothiourea) is a synthetic small molecule that acts as a reversible inhibitor of the bacterial actin homolog **MreB**, disrupting cell shape and division in rod-shaped bacteria such as *Pseudomonas aeruginosa*. A22 binds to the nucleotide-binding pocket of MreB, interfering with ATP binding, inhibiting MreB polymerization, and thereby disrupting the bacterial cytoskeleton. This morphological shift from rod to coccoid form impairs essential bacterial functions including nutrient uptake and cell division. Due to cytotoxicity and genotoxicity in human cells at higher concentrations, A22 is primarily used as a research tool for probing the prokaryotic cytoskeleton and for studying bacterial morphogenesis, rather than for clinical antibiotic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-(3,4-dichlorobenzyl)isothiourea.